CatalYm GmbH

📍 Meet us at AACR! Our colleagues Neha Vashist-Friedberger, Thorsten Ross and Eugen Leo are looking forward to the upcoming #AACR25, where they will present first preclinical data on combining our clinical-stage antibody visugromab with antibody-drug conjugates (ADCs) in an upcoming poster session. Our preliminary results demonstrate that GDF-15-blockade enhances the therapeutic activity of ADCs, potentially offering a new strategy to overcome cancer therapy resistance for solid tumors with high medical need. If you are attending the conference in Chicago, stop by our poster presentation and connect with our team to learn more about our versatile approach to improve cancer patients’ lives by advancing treatment options. #GDF15 #CancerResistance #CancerResearch

𝗧𝘄𝗼 𝗡𝗲𝘄 𝗣𝘂𝗯𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻𝘀 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝗶𝗻𝗴 𝗼𝘂𝗿 𝗣𝗶𝗼𝗻𝗲𝗲𝗿𝗶𝗻𝗴 𝗚𝗗𝗙-𝟭𝟱 𝗔𝗽𝗽𝗿𝗼𝗮𝗰𝗵 𝗶𝗻 𝗖𝗮𝗻𝗰𝗲𝗿 𝗧𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 This week, our promising clinical Phase 1/2 data for visugromab as well as our detailed insights in GDF-15’s underlying biology in the context of cancer were featured in two new scientific publications. Our recent clinical data published in 𝑁𝑎𝑡𝑢𝑟𝑒 (https://bit.ly/4cdr7S3) were discussed in a 𝑵𝒂𝒕𝒖𝒓𝒆 𝑴𝒆𝒅𝒊𝒄𝒊𝒏𝒆 article by Cheng, L.Y. 𝑒𝑡 𝑎𝑙. alongside Pfizer‘s ponsegromab data in cachexia. Based on our combined findings, the authors emphasize GDF-15 as a promising therapeutic target in cancer immunotherapy and cachexia, noting that GDF-15 inhibitors could play a transformative role in combination therapies as future treatment strategies. In an invited letter in 𝑪𝒍𝒊𝒏𝒊𝒄𝒂𝒍 𝒂𝒏𝒅 𝑻𝒓𝒂𝒏𝒔𝒍𝒂𝒕𝒊𝒐𝒏𝒂𝒍 𝑴𝒆𝒅𝒊𝒄𝒊𝒏𝒆, our colleagues Eugen Leo and Kathrin Klar, together with Ignacio Melero, International Coordinating Investigator of our GDFather-02 trial, provided a comprehensive overview of GDF-15’s multi-directional functions in a “vicious cycle” promoting cancer (immune-)therapy resistance and cachexia. The article highlights the potential of our GDF-15 neutralization approach to tackle both challenges simultaneously - thereby significantly improving the outcomes of several standard-of-care cancer treatments, particularly checkpoint inhibitors, as well as the quality of life of a broad patient population.  #CancerResearch #CancerResistance #Cachexia #GDF15

Our CMO, Eugen Leo,  is featured in Citeline’s “Scrip Asks…”, where over 140 biopharma share their expectations for advances in therapeutic areas in 2025. Many emphasized continued progress in oncology, with Eugen Leo highlighting the crucial need to overcome immune resistance and cachexia in cancer treatment.   At CatalYm, we are committed to addressing these challenges with our GDF-15-neutralizing antibody candidate, visugromab, which recently demonstrated remarkable outcomes in Phase 1/2 studies, significantly improving treatment responses in last-line, anti-PD-1 r/r solid tumors. The studies also showed promising results in reducing cachexia symptoms, greatly improving patient quality of life.   Check out the full article online at Scrip: https://bit.ly/4h6zjEc   Thank you, Eleanor Malone, for the coverage!   #CancerResearch #CancerResistance #Cachexia

💡Do you want to know more about new treatment options innovating the cancer immunotherapy space? 🎧 Check out the latest episode of Labiotech.eu’s Beyond Biotech podcast, where our CMO, Eugen Leo, explores the solid tumor landscape, discussing current treatment challenges, their underlying causes, and innovative strategies to address them. The podcast also provides insights on how the industry is working towards transforming cancer into a chronic, manageable disease. At CatalYm, we strive to transform cancer immunotherapy by leveraging our deep understanding of GDF-15’s role in mediating cancer resistance. Our GDF-15-neutralizing antibody, visugromab, showed impressive results in Phase 1/2 studies significantly improving the outcomes in last-line, anti-PD-1 r/r solid tumor patients. In addition, it also reduced cachexia symptoms that can severely impact a patient’s treatment tolerability and quality of life. Curious to learn more about our clinical program, its versatile potential to help a broad range of cancer patients, and our next steps to bring it to those in need? 🔗Listen to the full episode here https://lnkd.in/dhVQ9wXm or search for “Beyond Biotech” on your favorite podcast platform. A big thank you to Jim Cornall for the great interview! #BiotechInnovation

On this #WorldCancerDay, we stand #UnitedByUnique, recognizing the person behind each diagnosis and the distinct journey and complex challenges that every one of them faces. Their story is unique, and so is the need for new, innovative solutions that can offer hope where current therapies fall short.   At CatalYm, we are deeply committed to contributing to this effort by developing a novel approach to help those who are facing treatment resistance, a major limitation in cancer therapy impairing outcomes and patients’ quality of life. But today is about more than just science—it's about solidarity, compassion, and our shared goal to support the millions of people battling cancer worldwide.   Together, we can make a difference. 💪   #PatientsFirst #CancerResearch #CancerResistance

📜 𝙉𝘼𝙏𝙐𝙍𝙀 𝗽𝘂𝗯𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝗼𝗳 𝗩𝗜𝗦𝗨𝗚𝗥𝗢𝗠𝗔𝗕 𝗣𝗵 𝟭/𝟮𝗮 𝗗𝗔𝗧𝗔 𝗻𝗼𝘄 𝗶𝗻 𝗣𝗥𝗜𝗡𝗧📜   We are happy to see the 𝙉𝙖𝙩𝙪𝙧𝙚 print edition released today, featuring our phase 1/2a visugromab data (GDFATHER-01 trial), which were first published online on Dec 11, 2024.   The results highlight the great clinical potential of our GDF-15-blocking antibody candidate, visugromab, to reinvigorate, enhance, deepen and prolong checkpoint-inhibitor activity significantly - even in checkpoint-inhibitor relapsed/refractory patients.   We look forward to continuing our efforts in pushing the boundaries of cancer care by addressing therapy resistance and cachexia, two major factors impairing current treatment approaches!    #ICYMI: 🔗 Read more on the data here: https://lnkd.in/dE-AGe74   #Innovation #ScientificExcellence #ImmunoOncology #CancerResistance #GDF15 #Cachexia #Visugromab #CatalYm #CancerResearch

𝗖𝗮𝘁𝗮𝗹𝗬𝗺 𝗳𝗲𝗮𝘁𝘂𝗿𝗲𝗱 𝗶𝗻 @𝗢𝗻𝗰𝗼𝗭𝗶𝗻𝗲 Thank you to the OncoZine team for highlighting CatalYm’s innovative strides in cancer care!   This article dives into the compelling data recently published in Nature, showcasing how our lead candidate, visugromab, is advancing cancer immunotherapy. Featuring insights from Ignacio Melero, the International Coordinating Investigator of the GDFather trial, our CMO Eugen Leo, and our CSO Christine Schuberth-Wagner, the piece highlights visugromab’s ability to overcome resistance to anti-PD-(L)1 therapies in solid tumors, enabling more effective immune responses and improved patient outcomes. In addition to its immuno-oncology potential, visugromab shows promise in mitigating cachexia symptoms—a debilitating condition associated with cancer and treatment-induced muscle wasting—offering a dual benefit for patients. We’re proud to share this article as we push forward in our mission to transform cancer care. Read the full article here: https://lnkd.in/dU4FF7J8 #ImmunoOncology #CancerResistance #GDF15 #Cachexia #Visugromab #CatalYm #CancerResearch

𝗚𝗿𝗲𝗮𝘁 𝗻𝗲𝘄𝘀 𝘁𝗼 𝗸𝗶𝗰𝗸-𝗼𝗳𝗳 𝟮𝟬𝟮𝟱! 📣 Please join us in a warm welcome for our newly appointed CEO, Scott Clarke, who is taking the helm as our company enters a new stage of corporate and clinical development. Scott is a seasoned biopharma leader with over two decades of executive experience in driving company growth, developing products and shaping and executing transactions in the biopharmaceutical industry. His extensive expertise in oncology and partnering will be a substantial asset as we initiate a broad Phase 2b program with our lead candidate, visugromab, in hard-to-treat, metastatic #SolidTumor indications. Based in the US, he will oversee operations both in the EU and overseas, further solidifying our growing US presence. Read the full announcement here https://lnkd.in/esKRSU6z and visit www.catalym.com for more information on our GDF-15 neutralizing approach, which is uniquely positioned to reverse key resistance mechanisms and reinstate an efficient anti-tumor response.

2024 has been a remarkable year for us at CatalYm! 🎇 This year, CatalYm and our lead candidate #visugromab made significant strides: ✅ Publication in the prestigious scientific journal Nature, showcasing clinical proof of concept for overcoming resistance to checkpoint inhibitors. ✅ Presentations at key conferences, including trial updates at #ASCO2024 and the International Conference on Sarcopenia, Cachexia & Wasting Disorders (#SCWD), highlighting interim Phase 1/2 data on both cancer immunotherapy resistance and cachexia. ✅ Continued clinical advancements in our GDFATHER trial, delivering deep, durable responses in heavily pretreated patients. ✅ $150M financing round fueling the clinical development of visugromab and advancing its exploration in combination therapies and earlier treatment settings. In addition, we were honored to receive the Scrip Award for Best Oncology R&D Advance and the European Lifestars Award in the Late-Stage Venture Round/Series C+ Finance Raise of the Year category. These recognitions are a reflection of everyone at CatalYm, from the lab to the boardroom, and the growing recognition of GDF-15 as a novel and promising target in cancer treatment. We are deeply grateful to our exceptional team at CatalYm and our clinical partners for their unwavering support. A heartfelt thanks also goes to the #patients and their families for their trust and participation. Together, we are advancing innovative therapies to transform cancer treatment and improve lives. Here’s to a promising 2025—another year of breakthroughs and meaningful progress! #ImmunoOncology #GDF15 #CancerResistance #Cachexia #Visugromab #CancerResearch

We’ll be in San Francisco for the upcoming J.P. Morgan Healthcare Conference Week, January 13-16, 2025! We’re excited to connect with industry leaders and investors to discuss the latest trends in biotech.   This year, we’re particularly eager to highlight our innovations in cancer immunotherapy, focusing on our breakthroughs in overcoming cancer immunoresistance by neutralizing GDF-15, reflected by the recent publication of our Phase 1/2a visugromab data in 𝙉𝙖𝙩𝙪𝙧𝙚 https://lnkd.in/dE-AGe74. We’ll also share how targeting GDF-15 could significantly improve cancer patients’ quality of life and enhance their tolerance to standard of care therapies.   If you are attending as well and would like to meet up, reach out to us and say hi to our colleagues Anne Burger, Eugen Leo, Christine Schuberth-Wagner and Rob Sarisky.   #JPM2025 #ImmunoOncology #GDF15 #CatalYm #CancerResearch